GLP-1 drugs, body image, and the dysmorphia conversation on TikTok

What did @sloane.elizabeth actually say?

The creator is making two distinct predictions. First, that people who stop GLP-1 medications will regain weight and struggle with the psychological fallout of a changed body. Second, that watching peers become "stick thin" on these drugs is already generating body dysmorphia and unhealthy comparison, particularly among college-aged women. She frames GLP-1s as medications "meant for chronic illness" that require indefinite use, and worries about what happens when "the bubble inevitably bursts." These are not fringe concerns. They are real clinical and public health questions that researchers are actively studying, even if her framing leans more toward prediction than evidence.

Does the science back this up?

Partially, yes. The weight regain concern is well-documented. A 2022 study by Wilding et al. in Diabetes, Obesity and Metabolism found that participants who stopped semaglutide regained roughly two-thirds of their prior weight loss within one year. That is a real and significant finding that supports her core point about discontinuation consequences.

The body dysmorphia claim is harder to pin down with current data. Body dysmorphic disorder (BDD) and GLP-1 use have not been directly studied in large populations yet. What we do know is that social comparison on platforms like TikTok correlates with body dissatisfaction. A 2023 meta-analysis by Mingoia et al. in Body Image found that social media exposure to idealized bodies increases body dissatisfaction across age groups. Her extrapolation from "GLP-1 use is reshaping visible body norms" to "this will spike BDD diagnoses" is plausible but speculative at this point.

What did they get wrong (or right)?

She gets the chronic disease framing broadly right. GLP-1 receptor agonists were developed for type 2 diabetes management and obesity, both of which the American Medical Association classifies as chronic conditions requiring long-term treatment. The idea that these are "forever medications" for the conditions they treat is clinically accurate for most patients.

Where she oversimplifies: not everyone on GLP-1 drugs becomes "insanely lean" or "stick thin." Average weight loss on semaglutide in clinical trials is roughly 15 percent of body weight, which is meaningful but does not transform most users into an extreme body type. She is generalizing from an aesthetic norm visible on social media, which skews toward the most dramatic outcomes. That is worth calling out.

Her concern about college-aged women is grounded in real vulnerability data. A 2021 study by Lipson and Eisenberg in JAMA Network Open found that eating disorder rates among college students rose significantly between 2013 and 2020, before GLP-1s became culturally prominent. Adding a new body-norm driver into that environment is a legitimate concern, even without specific GLP-1 data yet.

What should you actually know?

A few things worth understanding if you are on a GLP-1 or considering one. Weight regain after stopping is real and expected, not a personal failure. It reflects the underlying biology of obesity regulation, not a lack of willpower. This is why clinical guidelines from the Endocrine Society support long-term or indefinite use for eligible patients.

Body image concerns around GLP-1 use are beginning to surface in clinical literature. A 2024 commentary in The Lancet Diabetes and Endocrinology raised concerns about patients developing unhealthy relationships with food restriction while on these medications. Behavioral health screening before and during treatment is increasingly recommended but inconsistently practiced.

If you are not on a GLP-1 and feel social pressure from watching peers use them, that experience is real and worth discussing with a mental health professional. It does not require a clinical diagnosis to be worth addressing. The creator's advice to "surround yourself with people in normal bodies" is well-intentioned but vague. What actually moves the needle, per research, is media literacy training and reducing passive social media consumption, not just changing your social circle.

Bottom line

@sloane.elizabeth is raising legitimate concerns with real clinical foundations, particularly around weight regain after discontinuation. Her body dysmorphia prediction is more speculative but not baseless. The weakest part of her argument is the implied universality of extreme thinness outcomes on GLP-1s, which overstates what average clinical results look like. Overall, this is a more evidence-adjacent take than most GLP-1 content on TikTok, but it should be taken as a starting point for conversation, not a clinical forecast.